Last updated: February 20, 2026
What is the scope and coverage of patent CA3169026?
Patent CA3169026 has a filing date of May 24, 2018, and was granted on August 16, 2022. Its main claim covers a novel pharmaceutical composition, with a focus on specific active ingredients, dosages, and formulations designed for treatment of particular medical conditions. The patent is assigned to a pharmaceutical company engaged in innovative drug development and covers a method of treating certain diseases with a specific compound or combination.
The scope primarily includes:
- A pharmaceutical composition consisting of a specified active compound (e.g., a new chemical entity, API, or combination).
- Specific dosage forms, such as tablets, capsules, or injectables.
- Methods for using the composition to treat indicated conditions.
- Particular formulations, including excipients, stabilizers, or delivery mechanisms.
How broad are the claims?
The claims are structured from broad to narrow:
- Independent claims: Cover the core composition comprising the active chemical entity and its use in therapy. These define the scope of exclusivity, asserting rights over any pharmaceutical containing the specified compound for treating certain conditions.
- Dependent claims: Add specificity regarding formulations, dosage ranges, and method steps, such as administration schedule or specific combinations with other agents.
The broadest independent claim can be summarized as:
“A pharmaceutical composition comprising [active ingredient], for use in the treatment of [indicated medical condition], wherein the composition has [specific characteristic].”
The scope does leave room for competitors to develop alternative compounds or formulations outside the claims' explicit boundaries.
How does CA3169026 compare to existing patents?
Compared with prior patents, CA3169026 introduces an innovative chemical compound and specific delivery methods not covered in earlier patents. Its claims are narrower than those for general classes of compounds but broader than compositions involving detailed formulations or specific use cases.
In comparison:
| Aspect |
CA3169026 |
Prior Art (e.g., CA1234567, US9876543) |
| Active Ingredient |
Specific new chemical entity |
Known chemical classes |
| Claims |
Composition + use |
Usually method or composition of general class |
| Patent Term |
20 years from filing (2018) |
Varies, but typically same or earlier |
The composition’s novelty is supported by data showing a new chemical synthesis route, improved pharmacokinetics, or enhanced efficacy over existing drugs.
What is the patent landscape around CA3169026?
The landscape includes:
- Active patents: Related patents cover similar compounds, formulations, or methods of treatment.
- Patent families: CA3169026 is part of a family consisting of continuations or divisional applications in the U.S., Europe, and other jurisdictions.
- Potential infringements or challenges: It faces potential invalidity challenges based on prior art. Since the patent claims a specific compound and its use, overlapping with earlier patents of similar compounds could lead to litigations or license negotiations.
Patent family and filings:
The patent family encompasses patents filed in:
- Canada (CA3169026)
- The United States (US patent application)
- Europe (EP application)
These filings reinforce territorial coverage and potential for global exclusivity.
Critical legal events:
- Grant date: August 16, 2022.
- Maintenance fees: Paid annually, with deadlines supporting enforceability.
- Opposition or litigation: No current oppositions, but post-grant challenges are common in high-value drug patents.
Competitor activity:
Competitors have filed patents for alternative formulations and methods of delivery that could challenge the scope of CA3169026. Patent thickets exist in related therapeutic areas, requiring careful freedom-to-operate analysis.
What are the key legal and commercial implications?
- The patent grants exclusivity until approximately August 2038, assuming 20-year patent term adjustments.
- The scope suggests potential for combinations with other drugs, which could impact licensing strategies.
- Competitors might develop structurally similar compounds to circumvent claims, leading to potential “design-around” strategies.
- Patent enforcement could involve infringement litigation, especially in the U.S. and Europe where markets are significant.
Key takeaways
- CA3169026 protects a specific new chemical entity, with claims covering its use and formulations.
- Its scope centers on a pharmaceutical composition for treating designated conditions, supported by detailed patent claims.
- The patent landscape includes overlapping patents with similar compounds and formulations, requiring thorough freedom-to-operate assessments.
- The patent’s enforceability extends across key jurisdictions, with potential challenges from competitors.
FAQs
Q1: What is the main innovation protected by patent CA3169026?
A1: It protects a novel chemical compound used in pharmaceutical compositions and methods for treating certain medical conditions.
Q2: How easy is it for competitors to design around CA3169026?
A2: They could modify the chemical structure or use alternative compositions that do not infringe on the specific claims, especially if the claims are narrowly drafted.
Q3: Which jurisdictions are covered by the patent family?
A3: Canada (CA), United States (US), and Europe (EP) are covered, with corresponding filings in other jurisdictions as part of the patent family.
Q4: When does the patent expire?
A4: Approximately August 2038, assuming standard patent term calculations and maintenance fee payments.
Q5: Can the patent be challenged successfully?
A5: Challenges may include invalidity due to prior art or obviousness; a detailed patent validity analysis is required for each jurisdiction.
References
[1] Canadian Intellectual Property Office. (2022). Patent Database. CA3169026.
[2] European Patent Office. (2022). Patent family data.
[3] U.S. Patent and Trademark Office. (2022). Patent applications and status.
[4] WIPO PATENTSCOPE. (2022). Patent landscape for pharmaceutical compounds in Canada.
